This press release has been sponsored by Medtronic.
Brainomix, a pioneer in stroke artificial intelligence (AI) imaging software has announced a strategic partnership with Medtronic Neurovascular, a global leader in medical technology. This collaboration aims to enhance stroke care across Western Europe by integrating cutting-edge AI solutions into clinical practice, improving patient outcomes and streamlining workflows.1
A transformative collaboration in stroke care
By combining Brainomix’s AI-powered imaging technology with Medtronic’s expertise in neurovascular treatments, the partnership represents a significant step forward in stroke diagnosis and treatment. The collaboration will support faster, more accurate diagnoses, enabling healthcare professionals to make better-informed decisions and deliver life-saving interventions more efficiently.
Alex Solich, senior consultant for neurointervention at Karolinska University Hospital (Solna, Sweden) and Örebro Hospital (Örebro, Sweden), emphasised the impact this partnership will have on patient outcomes: “As a stroke physician, I see firsthand the critical importance of speed and precision in delivering life-saving treatment. That’s why I’m genuinely excited about the partnership between Medtronic Neurovascular and Brainomix. Combining Medtronic’s proven neurovascular technologies with Brainomix’s AI-driven imaging has the potential to make a real difference—not just in streamlining workflows, but in giving patients a better chance at recovery. Knowing that we are moving toward more efficient, data-driven decision-making gives me great confidence that we can continue to push the boundaries of stroke care and improve outcomes for countless patients.”
Michalis Papadakis, chief executive officer (CEO) and co-founder of Brainomix, underscored the shared vision of both companies: “This partnership with Medtronic is a natural fit, with the leading neurovascular device provider joining forces with the leading stroke AI imaging partner, both aligned around a mutual commitment towards improving stroke care for all patients. We have demonstrated that our software impacts treatment rates and, working with Medtronic, we now have an opportunity together to deliver a solution for stroke networks across Europe that will enable more patients to gain access to vital stroke treatments.”
Matt Sturt, vice president, neurovascular Western Europe, Medtronic Neurovascular, said: “We are excited about our partnership with Brainomix. By combining Medtronic’s proven neurovascular technologies with Brainomix’s AI-driven imaging, we aim to enhance stroke care across Europe. This collaboration will streamline workflows, speed up decision-making, and ultimately give patients a better chance at recovery.1 Together, we are committed to pushing the boundaries of stroke care and improving outcomes for countless patients.”
Key benefits of the partnership
- Transforming treatment regionally: Medtronic’s established presence in Western Europe will accelerate the adoption of Brainomix’s AI technology, ensuring that life-saving innovations reach more hospitals and healthcare providers across the region.
- Enhanced diagnostic accuracy: Integrating Brainomix’s AI-powered imaging software with Medtronic’s neurovascular solutions will provide healthcare professionals with highly precise diagnostic tools2, enabling quicker and more informed decisions crucial for timely stroke treatment.1
- Optimised clinical workflows: By simplifying and accelerating stroke detection and intervention, this partnership will help alleviate the burden on healthcare providers and enhance efficiency across hospital networks.3
About Medtronic Neurovascular
With the largest neurovascular technology business in the world, Medtronic Neurovascular led evidence-based medicine in neurointervention with five landmark studies published in the New England Journal of Medicine in 2015. Its clinical and regulatory leadership and bold approach shaped the current guidelines for treating strokes.
About Brainomix
Brainomix specialises in AI-powered software solutions that enable precision medicine for better treatment decisions in stroke and lung fibrosis. Originally a spin-out from the University of Oxford (Oxford, UK), Brainomix is now an expanding commercial-stage company operating in more than 30 countries. A privately backed company supported by leading healthtech investors, Brainomix has developed award-winning imaging biomarkers and software solutions that are clinically adopted in hospitals worldwide.
To learn more about Brainomix and its technology, visit www.brainomix.com, and follow on X, LinkedIn and Facebook.
- Nagaratnam K et al. Artificial intelligence-based decision support software to improve the efficacy of acute stroke pathway in the NHS: an observational study. Front Neurol. 2024; 14: 1329643.
- Mallon D et al. Real-world evaluation of Brainomix e-Stroke software. Stroke Vasc Neurol. 2023; svn-2023-002859.
- Lip G et al. Adoption, orchestration, and deployment of artificial intelligence within the National Health Service—facilitators and barriers: an expert roundtable discussion. BJR|AI. 2024; 1(1): ubae009.
